Trial
NCT01823835
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Breast Cancer
Intervention
GDC-0810
Why stopped
The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-18